[The Epoch Times, March 20, 2022](The Epoch Times reporter Li Jing comprehensive report) The Chinese authorities have used domestic vaccines to vaccinate more than 1.2 billion people, but the epidemic in China is still severe. Recently, the authorities have not only imported Pfizer’s oral medicines in large quantities, but five Chinese companies have also obtained the production rights of its medicines.
Geneva Medicines Patent Pool (MPP) officially announced on Thursday (17th) that it has signed an agreement with 35 companies around the world to allow the generic production of nirmatrelvir, one of the ingredients of Pfizer’s oral drug Paxlovid. or preparations. Among them, there are 5 Chinese companies on the list.
The five Chinese companies on the list are Fosun Pharma, Huahai Pharmaceutical, Puluo Pharmaceutical, Jiuzhou Pharmaceutical and Shanghai Desano. Among them, Jiuzhou Pharmaceutical is authorized to produce APIs, and the other four can produce APIs and preparations at the same time.
Regarding the pricing of this drug, the relevant Chinese pharmaceutical companies did not specify.
Pfizer’s Paxlovid consists of two core components, nematevir and low-dose ritonavir. It is said that Nematevir, as the main ingredient, can inhibit the combination of the COVID-19 virus with the human body; Ritonavir can prolong the efficacy of Nematevir. In December 2021, Paxlovid received emergency use authorization from the U.S. Food and Drug Administration.
It is worth noting that this is not the first time a Chinese pharmaceutical company has been authorized to make generic COVID-19 oral medicines.
On January 20 this year, MPP’s official website announced that it had signed an agreement with 27 pharmaceutical companies to allow it to produce and supply Merck’s oral drug Molnupiravir to 105 low- and middle-income countries or regions around the world. Five Chinese pharmaceutical companies including Fosun Pharma are among them.
Merck & Co., Inc. is an American pharmaceutical company (known as “Merck” in the United States). As early as 1989, Merck transferred the world‘s most advanced genetically engineered recombinant hepatitis B vaccine to China, and instructed and trained Chinese personnel to set up a hepatitis B vaccine production factory. From 1994 to 2015, more than 200 million Chinese children have been effectively protected.
The two American drugs, Paxlovid and Molnupiravir, have been called by Chinese media as “special drugs” for epidemic prevention and the “nemesis” of mutated viruses.
Recently, the epidemic situation in various provinces and cities in China has rapidly heated up. Shenzhen, Dongguan, Quanzhou and other cities announced closures, Jilin closed the province, and Shanghai and Nanjing were closed in disguise.
On February 11, the Chinese Food and Drug Administration approved the import registration of Pfizer’s COVID-19 virus treatment drug Paxlovid. On March 15, according to the revised main points of the “New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Ninth Edition)” issued by the Chinese Communist Party’s Health and Health Commission, Paxlovid-specific anti-COVID-19 virus drugs were included in the diagnosis and treatment plan.
The Hong Kong government announced on March 15 that the first batch of oral anti-COVID-19 drug Paxlovid arrived in Hong Kong on March 14 and was sent to the Hospital Authority for use on the same day.
Recently, the Hong Kong epidemic broke out again. “Ming Pao” recently obtained the analysis data of the Hong Kong Hospital Authority on 5,167 deaths. Among these deaths, 1,486 people were vaccinated, of which 1,292 were vaccinated by Beijing Sinovac, accounting for 87%.
On the evening of March 17, 21,200 boxes of imported anti-COVID-19 virus drug “Nimatevir Tablets/Ritonavir Tablets” (Paxlovid) were inspected and released by the Shanghai Waigaoqiao Free Trade Zone Customs, and all import customs clearance procedures were completed. , quickly shipped to the country. This is the first batch of imported products in China after the drug was included in the latest version of the COVID-19 pneumonia diagnosis and treatment plan.
The Epoch Times reporter noticed that before the Chinese Food and Drug Administration approved the import of Pfizer Paxlovid, the state media had widely reported the side effects of the US vaccine to highlight the efficacy of the domestic vaccine.
According to official reports, as of March 17, the Chinese authorities have vaccinated more than 1.2 billion people with several domestically produced vaccines, with a cumulative reported dose of more than 3.2 billion. However, the side effects of China’s domestic vaccines have been criticized.
The Standing Committee of the Political Bureau of the Communist Party of China held a meeting on epidemic prevention and control on March 17, and the authorities once again demanded that the policy of “dynamic clearing” be adhered to.
Previously, the Chinese Communist Party has repeatedly emphasized “dynamic clearing”, while the public believes that “dynamic clearing” means closing the city. The epidemic in China has been going on for more than two years, and the CCP’s extreme epidemic prevention measures have made people’s lives difficult.
Responsible editor: Gao Jing#